- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05630508
Lifestyle Management App for Adults With Diabetes Type (LIVEN)
April 2, 2024 updated by: Shaima Alothman, Princess Nourah Bint Abdulrahman University
mHealth Lifestyle Management Program (LIVEN) For Adults With Diabetes Type 2: A Feasibility Study
This study will evaluate whether the 12-week health coaching mobile application (LIVEN) will succeed in enhancing lifestyle behaviors in adults with Type 2 Diabetes compared to typical treatment.
The mobile application's viability will be assessed in 2 parts; the first part is testing easiness and friendliness of using Liven by the patient and health coach.
The second part is evaluating the suitability of Liven education material for the patients and whether the coaching program results in enhancing lifestyle behaviors and blood sugar levels.
the investigators hypothesize that the 12-week online lifestyle-coaching program will be viable, and a full-scale study can proceed.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study will investigate the feasibility of a 12-weeks online lifestyle (nutrition and physical behavior) coaching program through a mobile app (LIVEN) compared to standard treatment for people with type 2 diabetes.
This study will be done in two phases; the first phase is the usability study (phase1), in which the user friendliness of the application will be assessed, and any technical flaws will be resolved prior and during the second phase.
The second phase of the study will consist of adapting a diabetes educational material and assessing the feasibility of the program (phase2).
the investigators hypothesize that the 12-week online lifestyle-coaching program will be feasible, and a full-scale study can proceed.
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shaima A Alothman, PhD
- Phone Number: +966503952053
- Email: shaalothman@pnu.edu.sa
Study Locations
-
-
-
Riyadh, Saudi Arabia, 11321
- Recruiting
- Princess Nourah bint Abdulrahman University
-
Contact:
- Shaima A Alothman, PhD
- Phone Number: +966503952053
- Email: shaalothman@pnu.edu.sa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults, aged 18 years or older
- Arabic speakers
- Capable of utilizing smartphones
- Diagnosed with T2DM
- Poor glycemic control: A1c > 7.5%
Exclusion Criteria:
- Individuals using insulin injection
- Individuals suffering from disorders that might affect intervention (e.g. amputation, enucleation of the eye, or end-stage kidney disease)
- Women who are pregnant or breastfeeding
- Individuals diagnosed with other types of diabetes (such as type I or MODY)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: interactive mhealth Lifestyle behavior intervention
Receiving Standard care, LIVEN educational material and interactive LIVEN application
|
Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
|
Sham Comparator: Sham group - app access only
Receiving standard care, LIVEN educational material and access to the application
|
Receiving standard care, LIVEN educational material and access to the application
|
No Intervention: Control group - Standard care
Receiving Standard care only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recruitment rate - descriptive
Time Frame: immediately after the intervention (3 months)
|
reported as the number of participants' consented divide by the number of people that were invited to participate
|
immediately after the intervention (3 months)
|
retention rates
Time Frame: immediately after the intervention (3 months)
|
reported as the number of participants completing all study sessions
|
immediately after the intervention (3 months)
|
User friendliness
Time Frame: Daily application engagement data for each patient will be analyzed once at the end of the patient's 12 week program.
|
will be assessed via user engagement tracking in the app
|
Daily application engagement data for each patient will be analyzed once at the end of the patient's 12 week program.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic control - A1c
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assess via A1c blood test will be reported as percentage.
higher % indicate worse outcome
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
Glycemic control - continuous glucose mentoring (CGM)
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assess via continuous glucose mentoring (CGM) as variability.
higher variability indicates worse outcome
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
Body composition - fat free mass (%) physiological parameter
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assessed via Bioelectrical Impedance Analysis (BIA).
fat free mass (%) will reported as percentage.
higher % indicate better outcome
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
Lifestyle behaviors - Health-Promoting Lifestyle profile II (Questionnaire)
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assessed via Health-Promoting Lifestyle profile II.
HPLP-II is a 4-point Likert scale with 52 items including six subscales: health responsibility, physical activity, nutrition, spiritual growth, interpersonal relationships, and stress management.
scores range from 52 to 208. higher scores indicate better outcome.
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
physical performance assessments - upper body muscle strength in kg
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assessed via Hand Grip Strength using dynameter (power in kg), higher scores indicate higher physical performance
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
physical performance assessments - lower body muscle strength in counts
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assessed via Sit to Stand Test (count), higher counts indicate higher physical performance
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
physical performance assessments - endurance
Time Frame: will be assessed one week prior to the intervention and one week after the end of the intervention
|
will be assessed via 6-minute walk test (distance in m).
higher distance indicates higher endurance
|
will be assessed one week prior to the intervention and one week after the end of the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2022
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
October 10, 2022
First Submitted That Met QC Criteria
November 18, 2022
First Posted (Actual)
November 29, 2022
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
April 2, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-0140
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on interactive Mhealth Lifestyle behavior intervention
-
The University of Texas Health Science Center at...National Institute on Aging (NIA); The Claude D. Pepper Older Americans Independence...CompletedType 2 Diabetes | Frailty | Weight, BodyUnited States
-
Boston CollegeJoslin Diabetes CenterCompleted
-
Sansum Diabetes Research InstituteRecruitingDiabetes Mellitus, Type 2 | Diabetes Mel Gestational - in PregnancyUnited States
-
Nova Southeastern UniversityRecruitingPosttraumatic Stress DisorderUnited States
-
National Institute of Diabetes and Digestive and...University of Massachusetts, WorcesterCompleted
-
University Hospitals, LeicesterUniversity of Leipzig; Technische Universität Dresden; University of Leicester; The Algarve Regional Health Administration and other collaboratorsCompletedObesity | Type 2 Diabetes | Chronic DiseaseUnited Kingdom
-
University of Kansas Medical CenterCompleted
-
University of ConnecticutNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Makerere UniversityInfectious Diseases Institute, UgandaCompletedmHealth | HIV-1-infection | ART AdherenceUganda
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingMigraine | Migraine Disorders | Headache | Headache Disorders | Chronic Migraine | Lifestyle FactorsUnited States